(212) 659-6222

Why People Are Turning
to Ketamine Assisted Therapy (KAT)

Millions of Americans are rethinking traditional psychiatric medications and for good reason.
Traditional SSRIs
Can take 6–8 weeks to begin working.

https://my.clevelandclinic.org/health/treatments/24795-ssri

Chronic, undesirable side effects that affect patients’ quality of life (weight gain, sexual dysfunction, and more) .

Cartwright C, Gibson K, Read J, Cowan O, Dehar T. Long-term antidepressant use: patient perspectives of benefits and adverse

effects. Patient Prefer Adherence. 2016 Jul 28;10:1401-7. doi: 10.2147/PPA.S110632. PMID: 27528803; PMCID: PMC4970636.

Nearly 50% of people with mental health conditions report that standard treatments don’t fully work.

https://www.ncbi.nlm.nih.gov/books/NBK361016/

High relapse rate (50-60%) after discontinuation.

Viguera AC, Baldessarini RJ, Friedberg J. Discontinuing antidepressant treatment in major depression. Harv Rev Psychiatry. 1998

Mar-Apr;5(6):293-306. doi: 10.3109/10673229809003578. PMID: 9559348.

Require continuous daily dosing, often for life.
Ketamine-Assisted Therapy (KAT)
Provides significant symptom reduction within hours of administration.

Zarate CA, Singh JB, Carlson PJ, et al. A Randomized Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Major

Depression. Arch Gen Psychiatry. 2006;63(8):856–864. doi:10.1001/archpsyc.63.8.856

Side effects are minimal, well known, and well-managed. They subside 1-2 hours after treatment.

Zarate CA, Singh JB, Carlson PJ, et al. A Randomized Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Major

Depression. Arch Gen Psychiatry. 2006;63(8):856–864. doi:10.1001/archpsyc.63.8.856

Response rates as high as 70.8% in clinical studies, even in patients with treatment-resistant depression.

Singh, J. B., Fedgchin, M., Daly, E. J., De Boer, P., Cooper, K., Lim, P., … Van Nueten, L. (2016). A Double-Blind, Randomized, Placebo-

Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression. American Journal of

Psychiatry, 173(8), 816–826. https://doi.org/10.1176/appi.ajp.2016.16010037

Sustained symptom relief lasting 3 months and beyond post-treatment.

Wilkinson, S. T., Farmer, C., Ballard, E. D., Mathew, S. J., Grunebaum, M. F., Murrough, J. W., … & Sanacora, G. (2018). Impact of

midazolam vs. ketamine on treatment response in a clinical trial of treatment-resistant depression. Psychopharmacology, 235(11),

3179–3188.

Short initial treatment series, followed by occasional maintenance sessions as needed.

How KAT Works
and Why It’s Different

Neuroplasticity & Repair
Ketamine promotes neuroplasticity — the brain’s ability to form new connections — by boosting BDNF and activating the mTOR pathway. This enhances synaptic plasticity, helping restore function in brain regions impacted by mood disorders.
A Therapeutic Window
These changes create an immediate “window of opportunity,” making the brain more receptive to new habits, thought patterns, and emotions — accelerating progress from the very first session.
Sustained Outcomes
The increased neuroplasticity extends beyond the treatment itself, enhancing the impact of psychotherapy and integration work, and helping patients achieve longer-lasting results.